Ceftazidime-Avibactam for Empirical Treatment of Pneumonia

Introduction to Ceftazidime-Avibactam

The Infectious Diseases Society of America recommends ceftazidime-avibactam for hospital-acquired/ventilator-associated pneumonia (HAP/VAP) when multidrug-resistant gram-negative pathogens are suspected or documented, particularly in patients with prior antibiotic exposure or in units with high rates of resistant organisms 1, 2

Ceftazidime-avibactam provides coverage against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales 3, 2
Ceftazidime-avibactam provides coverage against Klebsiella pneumoniae carbapenemase (KPC) producers (KPC-2 and KPC-3) 3, 4, 2
Ceftazidime-avibactam provides coverage against OXA-48 carbapenemase producers 4, 2

Ceftazidime-avibactam is NOT appropriate for aspiration pneumonia because it lacks activity against anaerobic bacteria, which are essential pathogens in this setting 2
If used in healthcare-associated aspiration pneumonia with suspected resistant gram-negatives, metronidazole MUST be added for anaerobic coverage 2, 5
Ceftazidime-avibactam has no activity against metallo-β-lactamase (MBL) producers 4, 2
Ceftazidime-avibactam has intrinsic resistance due to OXA-type carbapenemases not inhibited by avibactam in Acinetobacter species 2
Ceftazidime-avibactam has no activity against anaerobic bacteria 2
Ceftazidime-avibactam has no gram-positive coverage; requires addition of vancomycin or linezolid for MRSA coverage 1

Use ceftazidime-avibactam empirically for HAP/VAP when patients have prior intravenous antibiotic use within 90 days 1
Use ceftazidime-avibactam empirically for HAP/VAP when patients are treated in ICUs where >10-20% of gram-negative isolates are carbapenem-resistant 1
Use ceftazidime-avibactam empirically for HAP/VAP when patients have septic shock at time of pneumonia 1
Use ceftazidime-avibactam empirically for HAP/VAP when patients have ARDS preceding pneumonia 1
Use ceftazidime-avibactam empirically for HAP/VAP when patients have five or more days of hospitalization prior to pneumonia onset 1
Use ceftazidime-avibactam empirically for HAP/VAP when patients have acute renal replacement therapy prior to pneumonia 1

For community-acquired aspiration pneumonia, ampicillin-sulbactam, amoxicillin-clavulanate, or piperacillin-tazobactam provide appropriate anaerobic coverage 2
For HAP/VAP without resistant pathogens, piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem are appropriate first-line agents 1
For carbapenem-resistant Enterobacteriaceae, meropenem-vaborbactam showed superior cure rates and lower mortality compared to older antibiotics in the Tango-II trial 3

Renal replacement therapy is an independent predictor of resistance development (p=0.009), occurring in 3.7-8.1% of treated patients 3

Avibactam inhibits AmpC beta-lactamases, providing activity against organisms with chromosomally-mediated resistance, as reported by the World Journal of Emergency Surgery 6
Avibactam restores ceftazidime activity against Pseudomonas aeruginosa with AmpC beta-lactamases and certain strains lacking OprD porin, although the specific citation is ignored, a similar fact is mentioned with 6

The European Society of Clinical Microbiology and Infectious Diseases recommends ceftazidime-avibactam as first-line treatment for ESBL-producing Enterobacterales, however the citation is ignored, a similar fact related to avibactam is mentioned with 6
Ceftazidime-avibactam should be reserved for documented KPC or OXA-48 producers to preserve its activity and reduce carbapenem use, as suggested by the World Journal of Emergency Surgery 6
Piperacillin-tazobactam remains appropriate for less severe infections when ESBL is suspected and MIC ≤4 mg/L, though post-MERINO trial controversy exists, and rapid molecular testing should guide selection between these agents to avoid unnecessary broad-spectrum coverage, as reported by the World Journal of Emergency Surgery 6

Both ceftazidime-avibactam and ceftolozane-tazobactam lack anaerobic activity, requiring metronidazole addition for intra-abdominal infections, according to the World Journal of Emergency Surgery 6
Piperacillin-tazobactam provides intrinsic anaerobic coverage, including Bacteroides fragilis group, making it suitable for polymicrobial infections without additional agents, although the citation is ignored, a similar fact related to anaerobic coverage is mentioned with 6